Remissão da acromegalia após suspensão do tratamento farmacológico: estudo prospectivo multicêntrico

Página do item simplificado
dc.contributor.advisorAbucham Filho, Julio Zaki [UNIFESP]pt_BR
dc.contributor.advisorLatteshttp://lattes.cnpq.br/8325290942943257pt_BR
dc.contributor.authorCasagrande, Alessandra [UNIFESP]
dc.contributor.authorLatteshttp://lattes.cnpq.br/4395605872454369pt_BR
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)pt_BR
dc.coverage.spatialSão Paulopt_BR
dc.date.accessioned2018-07-27T15:49:33Z
dc.date.available2018-07-27T15:49:33Z
dc.date.issued2016-03-30
dc.description.abstractArtigo 1: Context: Long-term remission of acromegaly after somatostatin analogs withdrawal has been reported in 18-42% of patients in studies with relatively small number of patients using different inclusion and remission criteria. Objectives: To establish the probability and predictive factors for short-and long-term remission (normal IGF-1 for age/sex: IGF-1?1.00 xULN) after octreotide- LAR withdrawal in a larger population of well controlled patients with acromegaly (normal mean IGF-1 in the last 24 months). Design: Prospective, multicenter. Settings and Participants: Fifty-eight well controlled patients with acromegaly receiving only octreotide-LAR as primary or post-surgical treatment were included in 14 University centers in Brazil. All patients had been on stable doses and dose intervals of octreotide-LAR in the last year and no one had been submitted to radiotherapy. Intervention: Withdrawal of octreotide-LAR. Main outcome measurement: Serum IGF-1 after 8 (short-term) and 60 weeks (long-term) of octreotide-LAR withdrawal. Results: Seventeen of 58 patients (29%) were in remission in the short-term, but only four achieved long-term remission after treatment withdrawal. Kaplan-Meier estimated remission probability at 60 weeks was 7% and decreased to 5% at 72 weeks. Short-term remission rate was significantly higher (44%, P=0.017) in patients with pre-treatment IGF-1<2.4 xULN. No other predictive factor for short- or long- term remission was found. Conclusion: Long-term remission of acromegaly after octreotide-LAR withdrawal was an uncommon and frequently unsustainable event. In contrast, the much higher probability of short-term remission suggests that increasing dose intervals should be emphasized and routinely attempted in well controlled patients. Artigo 2: Purpose: Remission of acromegaly has been reported after somatostatin analogs withdrawal, but not after withdrawal of combination therapy with cabergoline, and only sporadically in patients controlled by cabergoline alone. Methods: To establish the remission rates (normal IGF-1 for age/sex: IGF- 1?1.00 xULN) after withdrawal of combined treatment with octreotide-LAR and cabergoline and cabergoline alone we prospectively studied 16 patients with acromegaly controlled by those treatments in the preceding two years as part of a larger study on remission of acromegaly after withdrawal of different medical treatments. Results: Among 97 patients with controlled acromegaly included in the entire study, only 16 patients had been on combination therapy (n=12) or cabergoline alone (n=4). At eight weeks after treatment withdrawal, three patients (19%) were in remission (short-term remission). At 60 weeks (long-term remission), IGF-1 levels were still in the normal range in two patients (12.5%) and remained normal up to 108 weeks after treatment withdrawal (last visit). One patient had been treated with cabergoline alone and another one with combination of octreotide and cabergoline before treatment withdrawal. Those two patients represent, respectively, 25% and 8.5% of remission rates according to type of previous treatment. Conclusion: Remission of acromegaly after withdrawal of treatment can also occur in patients with acromegaly controlled by cabergoline alone or cabergoline combined with octreotide.en
dc.description.sourceDados abertos - Sucupira - Teses e dissertações (2013 a 2016)
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior
dc.description.sponsorshipID528/11
dc.format.extent64 f.
dc.identifierhttps://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=3513847pt_BR
dc.identifier.citationCASAGRANDE, Alessandra. Remissão da acromegalia após suspensão do tratamento farmacológico: estudo prospectivo multicêntrico. 2016. 64 f. Tese (Doutorado em Endocrinologia Clínica) – Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, 2016.
dc.identifier.file2016-0569.pdf
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/46129
dc.language.isoeng
dc.publisherUniversidade Federal de São Paulo (UNIFESP)
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAcromegaliapt_BR
dc.subjectOctreotidapt_BR
dc.subjectErgolinaspt_BR
dc.titleRemissão da acromegalia após suspensão do tratamento farmacológico: estudo prospectivo multicêntricopt_BR
dc.title.alternativeRemission of acromegaly after medical treatment withdrawal: a prospective, multicentre studyen
dc.typeinfo:eu-repo/semantics/doctoralThesis
unifesp.campusEscola Paulista de Medicina (EPM)pt_BR
unifesp.graduateProgramMedicina (Endocrinologia Clínica)pt_BR
unifesp.knowledgeAreaCiências da saúdept_BR
unifesp.researchAreaMedicinapt_BR
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Alessandra Casagrande.pdf
Tamanho:
488.06 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
PPG - Medicina (Endocrinologia e Metabologia)